Stay updated with breaking news from Varoglutamstat Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
24.04.2024 - Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date ...
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s...
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext
Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and...